Lilly's Alzheimer’s Gamble Aims to Fill $10 Billion Gap

Loading player, please wait...

Recommended Videos

  • Info

  • Comments

July 13 (Bloomberg) -- With two Alzheimer’s drugs in the final stage of human testing and two more being developed behind them, Eli Lilly & Co. is committed to one of the riskiest bets in medicine to fill a potential $10 billion revenue gap. Bloomberg's Monica Bertran reports. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change